Please note: The information displayed on this page might be outdated.
Tricida, Inc.: Tricida is a late-stage pharmaceutical company focused on the development and commercialization of their drug candidate, TRC101, a non-absorbed polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract, or GI tract.
Healthcare/Drug Manufacturers
Based in...
North America
Public, USA
Market Cap
100MM - 500MM
United States

Company Participants at Tricida Analyst & Investor Event

  • Jackie Cossmon, VP, Investor Relations and Communications

Top 10 Holders of Tricida Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
OrbiMed Advisors LLC 19.41 9,614,280 87.20 13F 6/30/20
Wellington Management Co. LLP 9.71 4,808,703 43.61 13F 6/30/20
T. Rowe Price Associates, Inc. (Investment Management) 7.48 3,705,162 33.61 13F 6/30/20
The Vanguard Group, Inc. 5.14 2,544,071 23.07 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 5.12 2,535,796 23.00 13F 6/30/20
Redmile Group LLC 4.28 2,119,000 19.22 13F 6/30/20
BlackRock Fund Advisors 2.93 1,453,581 13.18 13F 6/30/20
Artisan Partners Holdings LP 2.51 1,244,223 11.29 13F 6/30/20
JPMorgan Investment Management, Inc. 2.04 1,008,719 9.15 13F 6/30/20
BlackRock Institutional Trust Co. NA 1.81 896,729 8.13 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.